Beneficial effect of Astragalus membranaceus on estimated glomerular filtration rate in patients with progressive chronic kidney disease

Okuda, Masumi; Horikoshi, Satoshi; Matsumoto, Mitsuhito; Tanimoto, Masuhisa; Yasui, Hiromichi; Tomino, Yasuhiko

doi:10.1016/j.hkjn.2012.01.001

Cited by 13 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The doses of astragalus root were determined based on the formula for dose translation as follows; rat dose (mg/kg) = human dose (mg/kg) × 37/6 [ 19 ]. The human dose of astragalus root for chronic kidney disease was 5,000 mg/body/day which was about 83 mg/kg/day assuming that the body weight was 60 kg [ 20 ]. Therefore, the rat equivalent dose of astragalus root calculated by the formula was about 514 mg/kg/day.…”

Section: Methodsmentioning

confidence: 99%

Renal protective effects of astragalus root in rat models of chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

Background Astragalus root is a commonly used herb in traditional Chinese medicine. Although renoprotective effects have been reported in some clinical and experimental studies, the details remain unknown. Methods We used 5/6 nephrectomized rats as chronic kidney disease (CKD) models. At 10 weeks, they were divided into four groups, namely, CKD, low-dose astragalus (AR400), high-dose astragalus (AR800), and sham groups. At 14 weeks, they were sacrificed for the evaluation of blood, urine, mRNA expression in the kidney, and renal histopathology. Results Kidney dysfunction was significantly improved following astragalus administration (creatinine clearance: sham group; 3.8 ± 0.3 mL/min, CKD group; 1.5 ± 0.1 mL/min, AR400 group; 2.5 ± 0.3 mL/min, AR800 group; 2.7 ± 0.1 mL/min). Blood pressure, urinary albumin, and urinary NGAL levels were significantly lower in the astragalus-treated groups than those in the CKD group. Excretion of urinary 8-OHdG, an oxidative stress marker, and intrarenal oxidative stress were lower in the astragalus-treated groups than those in the CKD group. Furthermore, the mRNA expression of NADPH p22 phox, NADPH p47 phox, Nox4, renin, angiotensin II type 1 receptor, and angiotensinogen in the kidney was lower in the astragalus-treated groups compared with the CKD group. Conclusion This study suggests that astragalus root slowed CKD progression, possibly through the suppression of oxidative stress and the renin–angiotensin system.

show abstract

Section: Methodsmentioning

confidence: 99%

Renal protective effects of astragalus root in rat models of chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A. membranaceus treatment has been shown to alleviate kidney dysfunction by ameliorating serum creatinine, uric acid, sodium, and potassium levels in aged rats [ 76 ]. This treatment also preserved stable levels of eGFR and postponed the entrance in renal replacement therapy in patients with progressive CKD stage 4 [ 77 ]. Meta-analysis of the beneficial effect and the clinical value of A. membranaceus has shown that Astragalus therapy prevents the progression of DN and improves renal functions (BUN, SCr, CCr, and urine protein) and serum albumin levels in patients with DN [ 78 , 79 ].…”

Section: Role Of Antioxidants In the Prevention Of Ckdmentioning

confidence: 99%

Molecular Mechanistic Pathways Targeted by Natural Antioxidants in the Prevention and Treatment of Chronic Kidney Disease

2021

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is the progressive loss of renal function and the leading cause of end-stage renal disease (ESRD). Despite optimal therapy, many patients progress to ESRD and require dialysis or transplantation. The pathogenesis of CKD involves inflammation, kidney fibrosis, and blunted renal cellular antioxidant capacity. In this review, we have focused on in vitro and in vivo experimental and clinical studies undertaken to investigate the mechanistic pathways by which these compounds exert their effects against the progression of CKD, particularly diabetic nephropathy and kidney fibrosis. The accumulated and collected data from preclinical and clinical studies revealed that these plants/bioactive compounds could activate autophagy, increase mitochondrial bioenergetics and prevent mitochondrial dysfunction, act as modulators of signaling pathways involved in inflammation, oxidative stress, and renal fibrosis. The main pathways targeted by these compounds include the canonical nuclear factor kappa B (NF-κB), canonical transforming growth factor-beta (TGF-β), autophagy, and Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid factor 2-related factor 2 (Nrf2)/antioxidant response element (ARE). This review presented an updated overview of the potential benefits of these antioxidants and new strategies to treat or reduce CKD progression, although the limitations related to the traditional formulation, lack of standardization, side effects, and safety.

show abstract

“…Astragalus is one of most extensively used herbs for cure renal disorders [16,[22][23]. It represents the largest genus of plants, comprising over 2000 species and found widespread in the world [24].…”

Section: Introductionmentioning

confidence: 99%

Interactions of Bioflavonoid Robinin With Efflux Transporters: P-Glycoprotein and Breast Cancer Resistance Protein

Tsiklauri

Alania

et al. 2023

View full text Add to dashboard Cite

Present study investigated the possible role of P-glycoprotein in the intracellular exposure of active substance (robinin) of natural medicine Flaroninum™ and effect of robinin on the cellular accumulation of mitoxantrone in either BCRP-overexpressing and BCRP-negative cells.Robinin -kaempferol-3-O--D-robinoside-7-O-α-L-rhamnopyranoside, has been obtained from over ground parts of Astragalus falcatus Lam., growing in Georgia. The compound possesses hypoazotemic and diuretic activities and is proposed for the complex therapy of kidney diseases. Pgp-overexpressing and P-gp-negative human breast cancer cells (MCF7) were used to examine the absorption character of kaempferol and robinin with or without of verapamil (P-gp inhibitor).Flavonoids concentrations were determined by LC/MS/MS. Robinin transport was P-gp-dependent and verapamil significantly increased the extent of uptake of robinin in cells, which is attributed in part to P-gp-inhibition by verapamil. When comparing the intracellular accumulation of aglycone with kaempferol-3-O--D-robinoside-7-O-α-L-rhamnopyranoside, we found that kaempferol uptake was greater than robinin. Since some glycosylated forms of flavonoids have been demonstrated to significantly suppress breast cancer resistance protein (BCRP/ABCG2), we hypothesized that kaempferol-3-O--D-robinoside-7-O-α-L-rhamnopyranoside may act as a BCRP-inhibitor. Mitoxantrone accumulation studies were performed in BCRP-overexpressing and BCRP-negative MCF7 cells using flow cytometric analysis. Robinin (5 and 50 M) had no significant impacts on the BCRP-mediated mitoxantrone transport; on the contrary, the aglycone kaempferol produced increased accumulation of mitoxantrone. From these results, we suggest that the active component of natural hypoazotemic medicine Flaroninum™, robinin, may be a substrate of P-gp and its efflux outside of the cells mediated P-gp may contribute to its decreased intracellular concentration.

show abstract

Beneficial effect of Astragalus membranaceus on estimated glomerular filtration rate in patients with progressive chronic kidney disease

Cited by 13 publications

References 19 publications

Renal protective effects of astragalus root in rat models of chronic kidney disease

Renal protective effects of astragalus root in rat models of chronic kidney disease

Molecular Mechanistic Pathways Targeted by Natural Antioxidants in the Prevention and Treatment of Chronic Kidney Disease

Interactions of Bioflavonoid Robinin With Efflux Transporters: P-Glycoprotein and Breast Cancer Resistance Protein

Contact Info

Product

Resources

About